Beijing Tide Pharmaceutical, NeuroDiscovery, Sosei deal

Sosei's Sosei Co. Ltd. subsidiary granted Beijing Tide worldwide rights, excluding Japan and other Asian countries, but including China, to SD118 (formerly NSL-043). The undisclosed small molecule has completed two Phase I trials for neuropathic pain. NeuroDiscovery said Beijing Tide plans to develop the product for the Chinese market. The biotech also said that upon clinical success or commercialization in China, Sosei may choose to have certain territories outside China reassigned to it. Sosei, which out-licensed the program to prioritize and focus development resources, is eligible for royalties. Sosei declined to disclose financial details. ...